Medication info

Risacare Injection

Prescription medicationInjectionsIntravenous injection
Ingredient · strength
L-Lysine Hydrochloride›25g / 1000mLL-Arginine Hydrochloride›25g / 1000mL
Manufacturer / importer
Novartis Korea Ltd.
Appearance
An injection solution that is a colorless and transparent liquid contained in a colorless and transparent bag for infusions.
Packaging
1000 milliliters/bag
Approval status
Active

MFDS item code 202104681 · Approved 2021.06.17

Summary

Main use
Reduction of renal radiation exposure during peptide receptor radionuclide therapy in adults
Who receives it
Adults
Adult administration
The recommended treatment regimen for adults is to administer one full bag of solution for injection together with lutetium (177Lu) oxodotreotide. Administer the entire contents of one bag of this medicine even if the PRRT dose is reduced. For optimal renal protection, administer by intravenous infusion (250 mL/hr) over 4 hours, starting 30 minutes before administration of lutetium (177Lu) oxodotreotide. Administer this medicine and lutetium (177Lu) oxodotreotide through separate intravenous lines in different arms. However, if intravenous administration is difficult or it is institutionally or clinically impossible to use 2 intravenous lines, this medicine and lutetium (177Lu) oxodotreotide may be infused through the same line via a 3-way valve, taking into account the flow rate and maintenance of intravenous access. This medicine is used during peptide receptor radionuclide therapy (PRRT, Peptide Receptor Radionuclide Therapy) with lutetium (177Lu) oxodotreotide and must be administered by a specialist experienced in PRRT. To reduce the occurrence of nausea and vomiting, administration of an antiemetic is recommended 30 minutes before infusion of this medicine. If severe nausea or vomiting occurs during infusion of this medicine despite administration of an antiemetic, an antiemetic from a different pharmacological class may be administered.

Ingredients

Importer
Novartis Korea Ltd.

Efficacy & effects

Reduction of renal radiation exposure during peptide receptor radionuclide therapy in adults

View approved original text

Peptide receptor radionuclide therapy (PRRT) using Lutetium-177 (177Lu) oxodotreotide is primarily used in the treatment of certain neuroendocrine tumors. During this treatment process, the kidneys can be exposed to radiation, so methods to reduce radiation exposure to the kidneys are applied to minimize kidney damage. The goal is to maintain the therapeutic effect while reducing side effects. Patients should understand that this treatment is effective for neuroendocrine tumor therapy and that radiation exposure to the kidneys is managed for safety.

How it is given

Adult administration

The recommended treatment regimen for adults is to administer one full bag of solution for injection together with lutetium (177Lu) oxodotreotide. Administer the entire contents of one bag of this medicine even if the PRRT dose is reduced. For optimal renal protection, administer by intravenous infusion (250 mL/hr) over 4 hours, starting 30 minutes before administration of lutetium (177Lu) oxodotreotide. Administer this medicine and lutetium (177Lu) oxodotreotide through separate intravenous lines in different arms. However, if intravenous administration is difficult or it is institutionally or clinically impossible to use 2 intravenous lines, this medicine and lutetium (177Lu) oxodotreotide may be infused through the same line via a 3-way valve, taking into account the flow rate and maintenance of intravenous access. This medicine is used during peptide receptor radionuclide therapy (PRRT, Peptide Receptor Radionuclide Therapy) with lutetium (177Lu) oxodotreotide and must be administered by a specialist experienced in PRRT. To reduce the occurrence of nausea and vomiting, administration of an antiemetic is recommended 30 minutes before infusion of this medicine. If severe nausea or vomiting occurs during infusion of this medicine despite administration of an antiemetic, an antiemetic from a different pharmacological class may be administered.

Precautions

This medication should not be used in patients who have had an allergic reaction to this drug or any of its components. Additionally, it should not be administered to patients with elevated serum potassium levels or severely reduced kidney function before administration. Caution is required when using this medication in patients with high serum potassium levels, severe heart failure, metabolic acidosis, or impaired kidney or liver function, and relevant tests should be conducted prior to administration. This medication mainly contains amino acids arginine and lysine; during administration, serum potassium levels may temporarily increase, so monitoring is necessary. In cases of hyperkalemia, symptoms may appear, so it is essential to closely observe for signs such as difficulty breathing, weakness, chest pain, and heart abnormalities. Sufficient fluid intake is recommended during the administration of this drug, and frequent urination is encouraged. In patients with severe heart failure, care must be taken with the volume and osmotic pressure of this medication due to the risk of complications. Attention should also be paid when administering to patients with metabolic acidosis, and most symptoms resolve within 24 hours post-administration. The safety of this drug has not been fully established in pregnant women or nursing mothers; consultation with a specialist is advised if necessary. The safety and efficacy of this drug have not been adequately studied in children or elderly patients, hence caution is needed when using. In patients with impaired kidney or liver function, functional tests should be conducted prior to administration, and the benefits and risks of treatment should be carefully considered if necessary. In cases of overdose, excessive fluid or solute may occur; forced diuresis or frequent urination should be used to promote excretion. This drug should not be mixed or diluted with other medications, and it should be stored at or below 25 degrees Celsius, being a single-use item that must be used immediately after opening. Do not use if the packaging is damaged, discolored, or if there are precipitates.

Side effects

  • nausea
  • vomiting
  • hyperkalemia
  • dizziness
  • headache
  • flushing
  • abdominal pain

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a sealed container to prevent exposure to air or moisture. Additionally, it is important to store it in a cool place at a temperature between 1 to 25 degrees Celsius to maintain its efficacy.

Appearance and packaging

Appearance

An injection solution that is a colorless and transparent liquid contained in a colorless and transparent bag for infusions.

Package unit

1000 milliliters/bag

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.